| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | - | - | - | 2.843 | 35.824 | 36.309 | 45.728 |
| Total Income - EUR | - | - | - | - | - | - | 2.847 | 35.943 | 36.312 | 45.906 |
| Total Expenses - EUR | - | - | - | - | - | - | 7.391 | 26.642 | 17.373 | 17.406 |
| Gross Profit/Loss - EUR | - | - | - | - | - | - | -4.545 | 9.301 | 18.940 | 28.500 |
| Net Profit/Loss - EUR | - | - | - | - | - | - | -4.630 | 8.423 | 18.620 | 27.192 |
| Employees | - | - | - | - | - | - | 0 | 1 | 1 | 1 |
Check the financial reports for the company - Genomica S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | - | - | - | 0 | 249 | 2.461 | 1.307 |
| Current Assets | - | - | - | - | - | - | 5.437 | 13.264 | 18.759 | 28.122 |
| Inventories | - | - | - | - | - | - | 0 | 0 | 0 | 0 |
| Receivables | - | - | - | - | - | - | 5.270 | 9.296 | 17.140 | 26.876 |
| Cash | - | - | - | - | - | - | 167 | 3.969 | 1.619 | 1.245 |
| Shareholders Funds | - | - | - | - | - | - | -4.590 | 3.819 | 19.791 | 27.240 |
| Social Capital | - | - | - | - | - | - | 40 | 41 | 40 | 40 |
| Debts | - | - | - | - | - | - | 10.026 | 9.694 | 1.428 | 2.189 |
| Income in Advance | - | - | - | - | - | - | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "6201 - 6201" | |||||||||
| CAEN Financial Year |
6201
|
|||||||||
Comments - Genomica S.r.l.